-+ 0.00%
-+ 0.00%
-+ 0.00%

TD Cowen Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $32

Benzinga·10/13/2026 15:59:02
TD Cowen analyst Dan Brennan maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $28 to $32.